Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproliferative interstitial lung disease (ILD) of uncertain cause with a median survival of 3 years from diagnosis. 1 IPF is strongly associated with smoking, and
case-control studies have demonstrated increased environmental and occupational exposure to a variety of industrial and organic inhalational agents in IPF. [2] [3] [4] [5] Cellular and animal models have shown an alteration of the alveolar epithelial cell phenotype in IPF characterized by apoptosis, fibroblast proliferation, and collagen deposition. [6] [7] [8] These findings suggest a conceptual model of IPF in which genetically susceptible individuals mount an aberrant response to repetitive low-level toxic exposure over time that induces progressive loss of functional alveolar epithelium and macroscopic scarring. 9 One potential source of repetitive toxic exposure is particulate air pollution. Ambient particles < 10 mm and < 2.5 mm in diameter (PM 10 and PM 2.5 , respectively) are composed of a complex mixture of organic chemicals, metals, and dusts, largely byproducts of hydrocarbon combustion, that are monitored and regulated by the Environmental Protection Agency (EPA). As the technology to measure daily atmospheric PM levels has improved, PM exposure has been implicated in a diverse range of systemic diseases, from atherosclerosis and diabetes to childhood autism. [10] [11] [12] [13] Ambient PM has been implicated in a wide variety of pulmonary diseases, from decreases in functional pulmonary measures in healthy patients to increased frequency of hospitalizations and mortality in patients with COPD and asthma. 14, 15 Short-term fluctuations in two other components of air pollution (ozone and nitrogen dioxide) have been associated with an increased risk of acute exacerbations of IPF, but the effect of ambient PM on long-term functional measures of disease progression is unknown. 16 We hypothesized that increased exposure to air pollution in the form of ambient PM would be associated with an accelerated rate of decline in pulmonary function in IPF.
Methods

Patient Population
The study population consisted of patients seen at a single university ILD referral center between 2007 and 2013 and who had at least two sets of pulmonary function test (PFT) results, including FVC. We considered the study entry point to be the first recorded FVC result in the medical record; therefore the study was composed of patients seen at follow-up and initial referral visits and included PFT results that preceded the implementation of the outpatient electronic medical record (EMR) in 2007. We initially identified subjects by EMR query for the standardized diagnostic code for IPF (International Classification of Disease, Ninth Revision code 516.31) and performed manual chart review to confirm that the subjects met 2011 American Thoracic Society (ATS) criteria for definite or probable IPF, as documented by a clinician with subspecialty expertise in the diagnosis and management of ILD, on the basis of clinical history and radiological and surgical pathologic examination (when available). In cases of diagnostic uncertainty, a comprehensive review of clinical history and radiological and surgical pathologic examination were presented to a multidisciplinary committee, including at least two ILD clinicians, a dedicated chest radiologist, and a pathologist, for adjudication based on 2011 ATS IPF criteria. The study was approved by the University of Pennsylvania Institutional Review Board (Protocol No. 817713).
Ascertainment of Exposure
Exposure to air pollution was characterized using a geospatial approach. The geographic catchment area of the referral center comprised urban, suburban, and rural areas within the greater Philadelphia metropolitan region. Subjects' home addresses were converted into latitude-longitude coordinates (geocoded) using ArcGIS, the industry standard professional geographic information system (GIS) software. 17 The air quality monitoring station location and local daily air quality data were pulled from the Air Quality Index (AQI), an online tool developed by the EPA. Pollution exposure was measured using daily mean concentration levels for PM 10 and PM 2.5 collected at the air quality monitoring station nearest the subjects' geocoded addresses. Local air quality monitoring site locations in the greater Philadelphia region varied during 2007 to 2013. This resulted in annual AQI data being unavailable for some subjects at certain times. To overcome these spatial and temporal limitations, all possible site locations were merged across time, enabling an assessment of the closest site reading to each subject's home address for each exposure variable.
Local daily air quality data collected between 2007 and 2013 were used to generate an individual mean value for each subject for each PM exposure variable from the date of their study entry (January 1, 2007 for subjects that entered prior to this date) through their date of study exit.
In addition, we computed a geospatial measure of automobile-derived air pollution. We used GIS road network data to identify the location and features of every road segment in the study area. nearest large road type: highway, state road (connect major cities), and large local roads (intrastate commerce and recreational travel).
Outcomes
The primary outcome was the rate of decline in FVC on serial PFTs, which is a reliable measure of disease status in IPF, a strong independent predictor of mortality, and the standard primary end point in clinical trials in IPF. [18] [19] [20] [21] All PFTs available for review from time of initial referral through the end of the study period were included in the analysis. To evaluate potential inconsistencies in FVC measurement, we conducted a sensitivity analysis including only tests performed at our university center's pulmonary function laboratory, which were performed by trained personnel according to standardized protocols and met ATS criteria for acceptability and reproducibility. [22] [23] [24] [25] To evaluate the possibility of a survivor effect or measurement error due to exposure preceding the study, we performed an additional sensitivity analysis excluding PFTs performed prior to January 1, 2007. Secondary end points included the rate of decline in the distance walked during the 6-min walk test (6MWT), number of liters of supplemental oxygen required to maintain oxygen saturation > 88% on the 6MWT, and all-cause mortality. All 6MWTs performed in our university's pulmonary function laboratory according to a standardized protocol were included in the analysis. 26 Mortality data were abstracted from the EMR, and vital status was additionally assessed using the Social Security Death Index (SSDI). If there was no documentation of mortality in the medical record or SSDI, all subjects with PFTs within 6 months of the study end point were assumed to be alive.
Statistical Analysis
All analyses were conducted in Stata, version 12.1 (StataCorp LLC). A longitudinal linear mixed-effects model with random intercept and random slope was chosen based on its assumptions regarding missing data (missing at random) and to account for individual variability in disease progression and severity at time of presentation. All outcome measures except mortality were continuous. Given the varied entry points and length of follow-up for individuals in this retrospective cohort, time was treated as linear and specified as the number of days since the first measurement of each outcome variable, with first measurement as day 1. The effect estimate and P values were drawn from the interaction between the exposure variable and time in a model, including main effects for exposure and time. Mortality analysis was conducted within a logistic regression model, using death at any point during the study period as the outcome. All outcomes were considered in independent models. Exposure variables were treated as continuous. Automobilederived air pollution was measured by the log-transformed distance from the subject's residence to the nearest major road, as the distribution was skewed and automobile-derived air pollution decays exponentially as distance increases. 27 After completion of initial analyses, potential confounders were added sequentially to the base model as covariates. Only variables that changed the point estimate of the ß-coefficient by > 15% were included in the final model. 28 Covariates assessed included study entry year; age; race; sex; baseline FVC; BMI; smoking status; the presence of comorbidities, including COPD, gastroesophageal reflux disease, pulmonary hypertension, and coronary artery disease; and use of medications, including systemic corticosteroids, N-acetylcysteine, and immunomodulatory agents, including azathioprine, mycophenolate, and methotrexate. The cohort predated the approval of pirfenidone and nintedanib. Age was continuous, and other variables were considered categorically. For longitudinal analyses, subjects were censored at time of death or lung transplantation. We estimated that a sample size of 130 subjects would provide > 80% power to detect a 5% difference in FVC change between dichotomous category of exposure (split at the median), assuming mean FVC of 50% predicted and SD of 10% in each group, at alpha ¼ 0.05.
Results
The initial EMR data query returned 238 subjects from Pennsylvania and New Jersey seen in our referral center between 2007 and 2013, 175 of whom had sufficient longitudinal data for inclusion. Twenty-six subjects (15%) missing exposure data were excluded from the study, and 14 subjects (8%) were determined to be misclassified as having IPF based on manual chart review and adjudication, leaving 135 subjects in the final analysis. Characteristics of the study population are presented in Table 1 . Excluded subjects had poorer baseline functional measures than did included subjects, but there were no significant differences in exposures between the groups (e- Table 1 ). PM 10 levels at all subjects' residences were less than the EPA National Ambient Air Quality Standards (NAAQS) throughout the study period, whereas PM 2.5 levels at some subjects' residences did not meet 2012 revised EPA NAAQS (although all levels were less than the 2006 NAAQS) (Fig 1) . The median number of PFT measurements per subject was five (IQR, 3-10).
There was a significant relationship between increased exposure to PM 10 and an accelerated FVC decline during the study period (P ¼ .019). Each 5 mg/m 3 increase in average ambient PM 10 concentration at subjects' residences corresponded with an additional 35 cc/y decline in FVC (95% CI, 6-65 cc/y) ( Table 2 ). Figure 2 demonstrates this association graphically, comparing FVC decline in subjects with PM 10 exposure greater than the median over the study period with those with less than median exposure. This relationship persisted in a model accounting for a wide variety of potential confounders. The main effect of PM 10 corresponded to an additional 46 cc/y decline in FVC (95% CI, 12-81 cc/y) ( Table 3 ; e- Table 2 ). In sensitivity analyses, this relationship did not significantly change when subjects whose PFTs were performed outside of our university health system or prior to 2007 were excluded (e- Table 3 ).
There was no significant relationship between ambient PM 2.5 and the rate of FVC decline or between any of our exposure variables and the rate of decline in 6MWT distance (Table 2) or the odds of mortality during the study period (Table 4 ). There was a significant relationship between increased exposure to PM 2.5 and an accelerated rate of increase in oxygen use on 6MWT ( significant relationships between PM 10 exposure and supplemental oxygen use or between road proximity and any of our outcome measures (e- Table 4 ).
Discussion
Our study demonstrates a significant relationship between exposure to ambient particulate matter (PM 10 ) and the rate of decline in FVC, a widely accepted indicator of disease progression in IPF. Higher PM 10 exposure levels were associated with an accelerated rate of decline, even as all PM 10 exposures met EPA NAAQS. The association between PM 10 and FVC decline suggests that exposure to air pollution may be a contributing factor in a dysregulated response to alveolar epithelial injury leading to fibrosis.
It is intriguing that a significant relationship was seen between exposure to coarse (PM 10 ) but not fine PM (PM 2.5 ) and the rate of decline in FVC, as there is an inverse relationship between particle size and penetration into distal airways, and a higher concentration of fine particulates (PM 2.5 ) reach distal airways in experimental models of particulate exposure. It is likely that our findings were influenced by the greater variability in PM 10 exposure seen in the geographic catchment area of the study, perhaps due to the more fully aerosolized nature of PM 2.5 (Fig 1) . Nevertheless, in the context of studies demonstrating aberrant responses in bronchial epithelium in IPF, our findings may suggest a broader epithelial dysfunction in the pathogenesis of IPF than has previously been apparent. 29, 30 The significant relationship between PM 2.5 exposure and increased use of supplemental oxygen in 6MWT over time lends strength to our primary finding and suggests that the cumulative burden of exposure to ambient PM, rather than a size-specific effect of PM 10 exposure, leads to an accelerated functional decline in IPF.
No association was seen between the proximity of subjects' residences to major roads and highways and any of our outcome measures. Previous studies of trafficrelated air pollution have demonstrated an exponential decline in the concentration of ambient particles as the distance from major roadways increases. Due in part to the size of the population included in the current study, there were very few subjects who lived within a short distance of a major road. This small sample size may have resulted in a failure to capture an association if one did exist.
This study included a wide geographic catchment area spanning urban and rural areas, which resulted in high variability in subject exposure to particulate pollution. This study has several important limitations. It is a singlecenter study of patients from a single, albeit diverse, geographic area, which limits the variability of exposure to PM, particularly PM 2.5 . In addition, an approach to exposure relying on listed residence in the EMR and data from regional monitoring stations limits the precision with which true PM exposure can be ascertained. Furthermore, confounding by environmental or subject-specific factors not captured in the medical record or selection bias due to differential loss to follow-up based on geographic factors unrelated to ambient air pollution may obscure the nature of the association.
Despite these limitations, this study demonstrated an association between exposure to ambient PM and important clinical indicators of disease progression in IPF. The identification of a potentially modifiable contributing factor to progression of disease through environmental exposure to particulate air pollution may have implications for the clinical management of the disease.
